European Commission Grants Marketing Authorization for Eisai's Zonegran for epilepsy
Main Category: EpilepsyArticle Date: 21 Mar 2005 - 0:00 PDT
email to a friend 
printer friendly 
view / write opinions 
rate article
Tokyo (JCNN) - Eisai announced on March 16 that its UK subsidiary Eisai Ltd. has received marketing authorization for Zonegran from the European Commission (EC) as of March 10.
This authorization allows the product to be marketed in EU countries for the adjunctive treatment for partial seizures of adult epilepsy patients.
Developed by Eisai, the zonisamide agent Zonegran is currently marketed in the US and Japan (trade name Excegran). By adding the product to its line of nerve drugs, the company aims to meet patients' needs and increase its presence in the EU.
View Eisai Co., Ltd. company profile here
Copyright © 2001-2004 JCNN. All rights reserved. A division of Japan Corporate News Network KK.
View drug information on Zonegran.
|
Please rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Epilepsy headlines email to a friend printer friendly version
weekly newsletter daily news alerts
personalize your news
rss feeds
back to top
Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
| Back to top | Back to front page | List of All Medical Articles |
| Privacy Policy | Terms and Conditions | © 2009 MediLexicon International Ltd |
